Cogent Biosciences, Inc. (COGT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Cogent Biosciences reported revenue of $0. Net income was -$328.9M, or -$2.16 per diluted share. Operating activities generated -$264.4M of cash, leaving -$266.0M of free cash flow. At fiscal year end, Cogent Biosciences held $937.6M in total assets against $301.2M in total liabilities, including $312.0M of cash and equivalents.
Open the full interactive Cogent Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Cogent Biosciences Key Stats
| Share Price | $28.09 |
|---|---|
| Market Cap | $4.80B |
| 52-Week Range | $14.13 – $42.84 |
| Shares Outstanding | 171.0 million (basic, 2026 Q2) |
Cogent Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $7.9M | $0 | $0 | $0 | $0 | $0 |
| Cost of Goods Sold | $90.1M | $75.6M | $147.8M | $208.1M | $275.9M | $333.4M |
| Gross Profit | -$82.2M | -$75.6M | -$147.8M | -$208.1M | -$275.9M | -$333.4M |
| Operating Income | -$82.2M | -$75.6M | -$147.8M | -$208.1M | -$275.9M | -$333.4M |
| Pre-Tax Income | -$74.8M | -$72.3M | -$140.2M | -$192.4M | -$255.9M | -$328.9M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$74.8M | -$72.3M | -$140.2M | -$192.4M | -$255.9M | -$328.9M |
| Diluted EPS | -$16.17 | -$1.87 | -$2.39 | -$2.42 | -$1.94 | -$2.16 |
Cogent Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$80.9M | -$102.5M | -$97.4M | -$96.4M |
| Diluted EPS | -$0.50 | -$0.80 | -$0.53 | -$0.52 |
Cogent Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $242.2M | $219.7M | $139.9M | $53.2M | $98.2M | $312.0M |
| Current Assets | $244.9M | $222.6M | $265.0M | $270.8M | $296.5M | $910.4M |
| Total Assets | $250.9M | $232.1M | $300.8M | $313.4M | $327.9M | $937.6M |
| Current Liabilities | $13.1M | $17.1M | $26.8M | $38.2M | $55.7M | $64.0M |
| Total Long-Term Debt | — | — | — | — | — | $222.9M |
| Total Liabilities | $16.2M | $17.9M | $45.1M | $55.6M | $71.6M | $301.2M |
| Shareholders' Equity | $234.7M | $214.2M | $255.7M | $257.8M | $256.3M | $636.4M |
Cogent Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$35.9M | -$58.8M | -$118.6M | -$153.6M | -$207.8M | -$264.4M |
| Cash From Investing | $8.4M | -$1.7M | -$124.7M | -$97.8M | $38.3M | -$399.5M |
| Cash From Financing | $232.2M | $38.0M | $163.6M | $163.5M | $214.5M | $878.2M |
| Free Cash Flow | -$35.9M | -$60.5M | -$125.5M | -$156.4M | -$208.4M | -$266.0M |
Figures from Cogent Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cogent Biosciences financials page for every line item.
Cogent Biosciences Company Profile
| Ticker | COGT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Waltham, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001622229 |
Frequently Asked Questions
What was Cogent Biosciences' revenue in fiscal 2025?
Cogent Biosciences (COGT) reported revenue of $0 for fiscal 2025.
What is Cogent Biosciences' annual revenue history?
Cogent Biosciences' annual revenue by fiscal year: 2020: $7.9M; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Cogent Biosciences' net income in fiscal 2025?
Cogent Biosciences reported net income of -$328.9M for fiscal 2025.
What was Cogent Biosciences' earnings per share (EPS) in fiscal 2025?
Cogent Biosciences' diluted EPS was -$2.16 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cogent Biosciences generate in fiscal 2025?
Cogent Biosciences generated -$266.0M of free cash flow in fiscal 2025.
What was Cogent Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cogent Biosciences reported revenue of $0.
How much debt does Cogent Biosciences have?
Cogent Biosciences reported $222.9M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Cogent Biosciences are outstanding?
Cogent Biosciences reported a weighted average of 171.0 million basic shares outstanding in 2026 Q2.
What is Cogent Biosciences' market cap?
Based on its latest closing price, Cogent Biosciences (COGT) has a market capitalization of about $4.80B.
When does Cogent Biosciences' fiscal year end?
Cogent Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Cogent Biosciences headquartered?
Cogent Biosciences lists its business address in Waltham, Massachusetts in its SEC filings.